CRON
Cronos Group Inc.
CRON's fundamentals are strong: revenue grew 56% and its operating margin went from −16% to 3.4%. At 21x earnings, it's trading above its usual 18x. Analysts expect that strong growth to continue.
CRON Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
CRON's revenue, profitability, cash flow and balance sheet are all currently healthy.
CRON PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 3.8x | $0.62 | -82% |
| Forward | 16x | $3.41 | — |
| Fair | 18x | $2.82 | -17% |
| Current | 21x | $3.41 | — |
| Expensive | 40x | $6.32 | +85% |
Historical ranges are pointers, not guarantees.
CRON's PE is in its fair range at 21x. If earnings grow as analysts expect, today's price would be 16x next year's earnings, in its cheap range.
CRON Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect strong earnings and revenue growth for CRON, with profitability improving.
CRON Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.22 | +38% |
| Q3 2026 | $0.16 | +45% |
| Q2 2026 | $0.19 | +217% |
| Q1 2026 | $0.00 | -100% |
| Q4 2025 | -$0.02 | -118% |
| Q3 2025 | $0.11 | +$0.24 |
| Q2 2025 | $0.06 | +$0.21 |
| Q1 2025 | $0.14 | +$0.29 |
| Q4 2024 | $0.11 | +$0.30 |
CRON's earnings per share have fallen from their peak: $0.16 over the past year, against $2.12 in late 2019.
CRON Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $63.5M | +75% |
| Q2 2026 | $53M | +58% |
| Q1 2026 | $45.2M | +40% |
| Q4 2025 | $44.5M | +47% |
| Q3 2025 | $36.3M | +6.1% |
| Q2 2025 | $33.5M | +21% |
| Q1 2025 | $32.3M | +28% |
| Q4 2024 | $30.3M | +27% |
CRON's revenue has grown year over year for 13 quarters in a row: $63M last quarter, up 75% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +16 points |
| Q2 2026 | 14% | +30 points |
| Q1 2026 | -4% | +8.6 points |
| Q4 2025 | -17% | +21 points |
| Q3 2025 | -1.4% | +97 points |
| Q2 2025 | -16% | +40 points |
| Q1 2025 | -13% | +51 points |
| Q4 2024 | -38% | +53 points |
CRON's operating margin was 14% last quarter, up 16 points from the same quarter a year ago, near the top of its range since 2020.
CRON Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $24.4M | +176% |
| Q2 2026 | $22.3M | +$23.3M |
| Q1 2026 | $9M | +$26.4M |
| Q4 2025 | $9.7M | +132% |
| Q3 2025 | $8.8M | +71% |
| Q2 2025 | -$1M | -200% |
| Q1 2025 | -$17.4M | -$13.4M |
| Q4 2024 | $4.2M | -73% |
CRON's free cash flow has turned positive again: $65M over the past year, against −$5M the year before.
CRON Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -4.3M shares |
| 1 year | -3.7% | -14.3M shares |
| 3 years | -2.7% | -10.4M shares |
| 5 years | -1.3% | -4.9M shares |
| Available history | +8.1% | +27.9M shares |
CRON has 371M diluted shares, down 3.7% from a year ago, with $47M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $9.4M |
| Q2 2026 | $16.1M |
| Q1 2026 | $16.7M |
| Q4 2025 | $4.3M |
| Q3 2025 | $1.9M |
CRON spent $47M buying back its own shares over the past year.
CRON Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -27.0x | Net Cash |
| Q2 2026 | -82.1x | Net Cash |
CRON has more cash than debt.
CRON Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.6 | Neutral |
| Stochastic | 62.5 | Neutral |
CRON's weekly RSI is 61 (neutral) and its Stochastic is 62 (neutral).
CRON PE vs Healthcare Sector
| Metric | CRON | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 26x | 18% below |
| PE % | 54 | 29 | 25 pts above |
CRON is trading at 21x earnings, a 18% discount to the Healthcare sector's median of 26x.
CRON Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.33 | 2.4% above |
| 20 week MA | $3.17 | 7.6% above |
| 50 week MA | $2.87 | 19% above |
| 100 week MA | $2.50 | 36% above |
| 200 week MA | $2.31 | 48% above |
CRON is in an uptrend: it's above all five of its weekly moving averages, and 48% above its 200-week average.
CRON Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.88 | $7.48 | +8.7% |
| 2021 | $7.48 | $4.26 | -43% |
| 2022 | $4.26 | $2.54 | -40% |
| 2023 | $2.54 | $2.09 | -18% |
| 2024 | $2.09 | $1.98 | -5.3% |
| 2025 | $1.98 | $2.66 | +34% |
| 2026 YTD | $2.66 | $3.41 | +28% |
CRON has finished lower in four of the last six years. It's up 28% so far in 2026.